News

Video

Putting Quality of Life into Perspective During CML Treatment

Author(s):

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning.

When discussing side effects from chronic myeloid leukemia (CML) treatment with the health care team, it is essential that patients state how their daily activities are affected, according to Claire Saxton.

In an interview at the 2024 American Society of Clinical Oncology Annual Meeting, Saxton, who is the executive vice president of Insights and Impact at Cancer Support Community, discussed the importance of quality of life while patients with CML undergo treatment.

“When you put things really in the perspective of how is this affecting your everyday life, your treatment team will be much better able to make sure that whatever treatment that you're on, it's the one that is giving you the best quality of life,” she said during an interview with CURE® at the conference.

WATCH MORE: 3 Questions to Ask Doctors After a CML Diagnosis

Transcript:

So, in the long term, the treatment journey really is how do we keep you having as few symptoms and side effects and as good a quality of life as possible. And so, being really clear with your treatment team [is important].

My fatigue means that I can't do some of my favorite things. … The fact that I have diarrhea means that I can't take the bus to work anymore.

When you put things really in the perspective of how is this affecting your everyday life, your treatment team will be much better able to make sure that whatever treatment that you're on, it's the one that is giving you the best quality of life.

Editor's Note: This program was made possible with support from Novartis Pharmaceuticals.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker
Related Content